Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP996473.RAQsGBZFbJ9Kwn9HUo0tn6B6Ez5TDr0Y3YOV2F2Kx0lG0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP996473.RAQsGBZFbJ9Kwn9HUo0tn6B6Ez5TDr0Y3YOV2F2Kx0lG0130_assertion type Assertion NP996473.RAQsGBZFbJ9Kwn9HUo0tn6B6Ez5TDr0Y3YOV2F2Kx0lG0130_head.
- NP996473.RAQsGBZFbJ9Kwn9HUo0tn6B6Ez5TDr0Y3YOV2F2Kx0lG0130_assertion description "[Overall, our data provide convincing evidence to suggest that pharmacologic inhibition of FGFR1 fusion kinases with ponatinib is likely to be beneficial for patients with SCLL and perhaps for other human disorders associated with dysregulated FGFR1 activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP996473.RAQsGBZFbJ9Kwn9HUo0tn6B6Ez5TDr0Y3YOV2F2Kx0lG0130_provenance.
- NP996473.RAQsGBZFbJ9Kwn9HUo0tn6B6Ez5TDr0Y3YOV2F2Kx0lG0130_assertion evidence source_evidence_literature NP996473.RAQsGBZFbJ9Kwn9HUo0tn6B6Ez5TDr0Y3YOV2F2Kx0lG0130_provenance.
- NP996473.RAQsGBZFbJ9Kwn9HUo0tn6B6Ez5TDr0Y3YOV2F2Kx0lG0130_assertion SIO_000772 22781593 NP996473.RAQsGBZFbJ9Kwn9HUo0tn6B6Ez5TDr0Y3YOV2F2Kx0lG0130_provenance.
- NP996473.RAQsGBZFbJ9Kwn9HUo0tn6B6Ez5TDr0Y3YOV2F2Kx0lG0130_assertion wasDerivedFrom befree-2016 NP996473.RAQsGBZFbJ9Kwn9HUo0tn6B6Ez5TDr0Y3YOV2F2Kx0lG0130_provenance.
- NP996473.RAQsGBZFbJ9Kwn9HUo0tn6B6Ez5TDr0Y3YOV2F2Kx0lG0130_assertion wasGeneratedBy ECO_0000203 NP996473.RAQsGBZFbJ9Kwn9HUo0tn6B6Ez5TDr0Y3YOV2F2Kx0lG0130_provenance.